Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$20.87MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Troy Wilson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 260
- Beta
- 0.38
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.71
Financials
Revenue
$20.87M+756.9%Net Income
$-68.33MEBITDA
$-65.61MFree Cash Flow
$-63.20MEPS (diluted)
$-0.77Shares Outstanding (diluted)
88.86M+371.4%Operating Expenses
$93.64MCash & Debt
$519.02MRevenue by Segment (annual)
$67.48MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $67.48M | $-278.67M | $-3.18 |
| 2024 | $53.88M | $-173.98M | $-2.02 |
| 2023 | $0.00 | $-152.63M | $-2.08 |
| 2022 | $0.00 | $-135.84M | $-2.03 |
| 2021 | $0.00 | $-130.47M | $-1.97 |
| 2020 | $0.00 | $-89.63M | $-1.69 |
| 2019 | $0.00 | $-63.14M | $-1.51 |
| 2018 | $0.00 | $-60.45M | $-1.72 |
| 2017 | $0.00 | $-35.43M | $-1.52 |
| 2016 | $0.00 | $-27.56M | $-1.47 |
| 2015 | $0.00 | $-22.63M | $-2.28 |
| 2014 | $0.00 | $-11.01M | $-2.69 |
| 2013 | $0.00 | $-27.3K | $-0.01 |
| 2012 | $0.00 | $-27.0K | $-0.01 |
Valuation
KURAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (14)
- Newsglobenewswire.com·7d ago·Positive
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes – KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
…ercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026.
View source ↗ - Newszacks.com·35d ago·Positive
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Kura Oncology to Participate in Three Investor Conferences in September SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m.
View source ↗ - Newszacks.com·35d ago·Positive
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock? Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI's FDA approval and robust early commercial performance in relapsed/refractory NPM1-mutated AML. The company achieved $9.1M net product revenue in two quarters, marking a 57% sequential increase, and targets significant market expansion via first-line AML indications. Phase 3 KOMET-017 trial topline data in 2028 and two p
View source ↗ - Newszacks.com·47d ago·Positive
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy? Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·48d ago·Positive
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect? The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Negative
Kura Oncology Q2 Earnings Call Highlights Kura Oncology NASDAQ: KURA reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said the drug captured a majority share of new patient starts in the menin inhibitor market for that indication.
View source ↗ - Newszacks.com·54d ago·Neutral
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates Kura Oncology (KURA) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.75 per share a year ago.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Kura Oncology Reports Second Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity – Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.81 per share
Typical surprise -27.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.77 vs $-0.88beat
- Tue, May 12$-0.83 vs $-0.88beat
- Thu, Mar 5$-0.92 vs $-0.72miss
- Tue, Nov 4$-0.85 vs $-0.57miss
- Thu, Aug 7$-0.75 vs $0.15miss
- Thu, May 1$-0.66 vs $-0.51miss
Estimates and results for KURA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KURA officers and directors.
- Bought
- $3.1m
- Sold
- $4.5m
5 trades
46 trades
- Ford Kathleensold
- Leoni Molliesold
- Powl Brian T.sold
- Bair Teresa Brophysold
- Ford Kathleensold
- Leoni Molliesold
- Doyle Thomas Jamessold
- Powl Brian T.sold
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.